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Hepatitis C virus (HCV) infection often leads to the development of hepatocellular carcinoma (HCC), but its molecular
mechanism has not been clearly elucidated. Previously, transgenic mice constitutively expressing HCV core protein have
been shown to develop HCC, suggesting a pivotal role of the core protein in hepatocarcinogenesis. Here, we analyzed the
expression of cytokines associated with a variety of cellular processes, including cell proliferation, in the mouse model for
HCV-associated HCC to define the molecular events prior to oncogenesis. The expression of tumor necrosis factor- and
interleukin-1 was increased at both protein and mRNA levels. In addition, the activities of c-Jun N-terminal kinase and
activator protein-1 (AP-1), downstream effectors, were enhanced, while IB kinase or nuclear factor-B activities were not
enhanced. Thus, the altered in vivo expression of cytokines with AP-1 activation in consequence to the core proteinKey Words: HCV; core protein; transgenic mouse; TNF-
Hepatitis C virus (HCV) is a causative agent of acute
and chronic non-A non-B hepatitis (Choo et al., 1989).
HCV infection frequently persists and leads to liver cir-
rhosis and hepatocellular carcinoma (HCC) (Saito et al.,
1990). However, the mechanism of hepatocarcinogen-
esis in HCV infection is not clearly understood.
The core protein of HCV, by interacting with its viral
RNA, forms a viral nucleocapsid (Shimoike et al., 1999).
In addition to this genome-packaging function, the core
protein has various functions. The core protein trans-
forms fibroblasts with or without the cooperation of the
ras oncogene, suppresses or enhances apoptosis of
cultured cells, modulates the transcription of some
genes, and binds to some cellular proteins (Lai and
Ware, 2000; McLauchlan, 2000; Suzuki et al., 1999). In
addition, we have reported that transgenic mice express-
ing the core protein in the liver develop HCC (Moriya et
al., 1998). These results indicate that the core protein is
closely associated with hepatocarcinogenesis in HCV
infection.
Cytokines are important mediators of tissue injury and
inflammation. The cytokine signal is transmitted to cells
via membrane-bound receptors. This cytokine–receptor
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interaction activates intracellular signaling pathways.
Cytokine-inducible transcription factors, including activa-
tor protein-1 (AP-1) and nuclear factor-B (NF-B), inter-
act with their responsive elements in the promoter re-
gions of various genes. Cytokines like tumor necrosis
factor- (TNF-), interleukin (IL)-1, and IL-6 are closely
associated with liver regeneration. Treatment with anti-
bodies to TNF- before partial hepatectomy resulted in
decreased DNA synthesis and an abrogation of in-
creases in c-Jun N-terminal kinase (JNK), c-jun mRNA,
and nuclear AP-1 activity (Diehl et al., 1994). In addition,
mice lacking the type I TNF receptor were deficient in
liver regeneration (Yamada et al., 1997). Concerning IL-6,
hepatocyte DNA synthesis during liver regeneration was
suppressed in mice carrying a homozygous deletion of
the IL-6 gene (Cressman et al., 1996). Taken together, the
cytokines described above are considered as playing
important roles in cell proliferation and, possibly, hepa-
tocarcinogenesis.
TNF-, IL-1, and IL-6 are mainly synthesized by blood
cells like lymphocytes and monocytes, but the liver is
also an important producer of these cytokines. Human
and murine hepatocytes as well as Kupffer cells produce
TNF-, IL-1, and IL-6 (Andus et al., 1991; Gonzalez-Amaro
et al., 1994; Hunt et al., 1992; Wordemann et al., 1998).
Since TNF- signaling plays important roles in a wide
range of cellular functions, including inflammation, cellexpression may contribute to hepatocarcinogenesis in per
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pathogeneses by influencing TNF- signaling pathways.
In fact, several previous reports showed an association
or interaction of the core protein with TNF- signaling
pathways (Chen et al., 1997; Marusawa et al., 1999;
Matsumoto et al., 1997; Shrivastava et al., 1998; Zhu et al.,
1998). However, carcinoma or transformed cell lines
were used to express the core protein, and some con-
flicting evidence was observed in these studies.
Here we demonstrate the enhancement of TNF- and
IL-1 expression in the liver of core-transgenic mice in
the absence of inflammation in the liver. In these mice,
the activation of JNK and transcription factor AP-1, which
are downstream effectors of these cytokines, was also
demonstrated. These results suggest that the core pro-
tein potentially enhances the hepatic expression of
TNF- and IL-1 and activates AP-1 in vivo, contributing
to hepatocarcinogenesis.
RESULTS
HCV core protein modulates intrahepatic cytokine
expression in the liver of core-transgenic mice
Cytokines such as TNF-, IL-1, and IL-6 are closely
associated not only with controlling proliferation of hepa-
tocytes, but also with various pathogeneses of the liver,
including regeneration, necrosis, inflammation, fibrosis,
and, possibly, carcinogenesis (Andus et al., 1991). The
liver is an important source of production of these cyto-
kines as well as the main scavenger for them (Andus et
al., 1991). Therefore, we first investigated the gene ex-
pression profiles of the above cytokines in the liver of
core-transgenic mice. In this study, we used pairs of
young, 2- to 3-month-old transgenic mice and their litter-
mates for the following reasons. First, we aimed to as-
sess the direct in vivo effect of the core protein in the
liver. Second, we wanted to use core-transgenic mice
with histopathological changes of the liver that were as
slight as possible without advanced steatosis or HCC
because these pathological changes themselves might
modulate cytokine expression. The levels of the core
protein in the liver of core-transgenic mice were within
the range of those in livers of HCV-associated HCC
patients (Koike et al., 2002).
We determined intrahepatic mRNA expression of cy-
tokines by RT–PCR. Figure 1A shows the mRNA expres-
sion of TNF- and IL-1 in the liver of core-transgenic
mice of 2 to 3 months old and that of nontransgenic
control mice of the same ages. The expression of the
housekeeping gene, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), was also examined. In spite of a
lack of inflammation in the liver of core-transgenic mice,
gene expression of these cytokines was enhanced in
core-transgenic mice compared to that of nontransgenic
littermates. The expression levels of the GAPDH gene
were similar in all of the samples, indicating that the
amount of mRNA used and the efficiency of the amplifi-
cation were almost equal. A similar tendency was also
observed when we decreased the cycles of the PCR by
five, indicating that the PCR products were not saturated.
On the other hand, the gene expression of IL-6 as well as
of -actin in the liver of core-transgenic mice was prin-
cipally similar to that of nontransgenic mice (Fig. 1B).
Such modulation of the cytokine gene expression was
observed in the mice from two independent lines. We
further performed TaqMan real-time PCR to quantify
TNF- and IL-1 mRNA in the liver of mice. For statistical
analysis, we examined three more pairs of mice in ad-
dition to those used for the above experiment. One hun-
dred nanograms of total RNA was amplified, and the
amount of the PCR products was recorded at each cycle.
mRNA copy numbers calculated from the calibration
curves were normalized against GAPDH, the expression
of which was not altered by the core protein in mice (data
not shown). As shown in Table 1, the mRNA levels of
TNF- and IL-1 in the liver of core-transgenic mice were
increased 2- to 2.5-fold and 1.5- to 2-fold, respectively.
These results suggest that the expression of the core
protein enhances intrahepatic gene expression of the
cytokines TNF- and IL-1 in core-transgenic mice.
To assess whether these enhanced gene expressions
reflected the intrahepatic protein levels, we next deter-
mined the protein expression of TNF- and IL-1 in the
liver of these mice. The amount of TNF- and IL-1 was
determined by ELISA using mouse liver lysates and di-
vided by the amount of liver total proteins. As shown in
Table 2, both the TNF- and IL-1 protein levels were
FIG. 1. mRNA expression of cytokines in the liver of core-transgenic
(T) and nontransgenic (NT) mice by RT–PCR. Total RNA was extracted
from the liver of mice and RT–PCR (30 cycles) was performed using
adequate primers. (A) mRNA expression of TNF- and IL-1 in three
pairs of 2- to 3-month-old mice. The GAPDH gene was used as an
internal control. After PCR products were separated on the gel, South-
ern blot analysis was performed to confirm an adequate amplification
of TNF- and IL-1 genes. (B) mRNA expression of IL-6 in the same
pairs of as mice shown in (A). The -actin gene was used as an internal
control.
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significantly increased in the livers of core-transgenic
mice compared to nontransgenic littermates. The ratios
(core-transgenic/nontransgenic) of the TNF- and IL-1
protein levels were 1.9 and 2.3, respectively, which were
slightly different from those of the mRNA levels (2.4 and
1.8, respectively). We cannot clearly show the reason for
this, but one possible explanation is that possible post-
transcriptional modifications work for the protein expres-
sion of the cytokines as reported previously (Chantry et
al., 1989; Moller et al., 1998). We also determined the
protein expression levels of these cytokines in the livers
of the mice expressing HCV envelope proteins under the
same regulatory region as that of the core-gene-trans-
genic mice (Koike et al., 1997) and found similar expres-
sion levels in envelope-transgenic and control mice (data
not shown).
HCV core protein activates the JNK–AP-1 pathway in
the liver of core-transgenic mice
TNF- and IL-1 bind to their specific receptors on the
cell surface and activate intracellular signaling cas-
cades. One of the well-known pathways is JNK–AP-1; JNK
is activated by TNF-- or IL-1 stimulation and phosphor-
ylates c-Jun, leading to AP-1 activation (Angel and Karin,
1991). Therefore, we examined whether this pathway
was modulated in the liver of core-transgenic mice. First,
we determined JNK activity by in vitro kinase assay. As
shown in Fig. 2A, the JNK activity was increased in the
livers of core-transgenic mice. Densitometry showed that
the JNK activity was increased approximately 2.5-fold
compared to that of nontransgenic mice. This was al-
most consistent with the result that the expression of
both TNF- and IL-1 was about 2-fold increased in the
liver of core-transgenic mice (Table 2). We also deter-
mined the activity of extracellular signal-regulated kinase
(ERK) and found similar activation between core-trans-
TABLE 2
Protein Levels of TNF- and IL-1 in the Livers of Transgenic and
Nontransgenic Mice
Transgenic mice
(n  7)
Nontransgenic mice
(n  7) Pa
TNF- 600.5 (311.0)b 323.4 (114.6) 0.05
IL-1 1387.3 (565.8) 610.6 (160.6) 0.05
a Mann-Whitney’s U test.
b Picograms/milligrams total proteins (means  SE).
TABLE 1
mRNA Levels of TNF- and IL-1 in the Livers of Transgenic and
Nontransgenic Mice
Transgenic mice
(n  6)
Nontransgenic mice
(n  6) Pa
TNF- 1.30 (0.74) 102b 0.54 (0.13) 102 0.05
IL-1 2.25 (0.72) 102 1.24 (0.24) 102 0.05
a Mann–Whitney’s U test.
b Values are expressed in mRNA copy numbers quantified by real-
time PCR, followed by normalization against levels of GAPDH
(means  SE).
FIG. 2. The activity of JNK and ERK in the liver of core-transgenic (T) and nontransgenic (NT) mice determined by an in vitro kinase assay. The in
vitro kinase assay was performed using commercially available kits. (A) JNK; (B) ERK. The lower panels show densitometric analysis of the blots. The
values were normalized by taking the density of nontransgenic mice as 1 (relative kinase activity). The data shown are means  SE (n  3 for each
sample group). *Mann-Whitney’s U test; N. S., no statistically significant difference.
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genic and nontransgenic mice (Fig. 2B). This indicates
that JNK was selectively activated in core-transgenic
mice.
We next determined the AP-1 activation in the liver of
core-transgenic and nontransgenic mice. As shown in
Fig. 3A, the activation of AP-1 in core-transgenic mice
was markedly enhanced compared to that in nontrans-
genic littermates. Densitometry showed that the level of
AP-1 activity was about two times higher in these trans-
genic mice. The same amount of nuclear proteins used
in the assay was stained by Coomassie brilliant blue
after separation by SDS–PAGE (Fig. 3A, lower panel),
indicating that a similar amount of nuclear proteins was
used between core-transgenic and nontransgenic
mouse. We confirmed the specificity of this band by
adding 50-fold, unlabeled, identical or different oligonu-
cleotides (Fig. 3B). These results indicate that the JNK–
AP-1 pathway was activated in the liver of core-trans-
genic mice.
AP-1 consists of c-Jun and c-Fos, and the expression
of c-jun and c-fos is regulated mainly by JNK–AP-1 and
ERK-SRE, respectively. Therefore, we determined the
gene expression of c-jun and c-fos by RT–PCR. As shown
in Fig. 3C, c-jun but not c-fos expression was increased
in the liver of core-transgenic mice. In addition, the ex-
pression of the collagenase gene, which is known to be
regulated by AP-1 (Angel et al., 1987), was increased in
the liver of core-transgenic mice (Fig. 3C). Semiquantita-
tive comparisons of the mRNA abundance revealed that
the expression of c-jun and collagenase was increased
about two- to threefold in the liver of core-transgenic
mice, whereas the expression of c-fos as well as -actin
was similar. These results indicate that AP-1 activation
actually modulated the responsible gene expression in
core-transgenic mice.
HCV core protein does not activate the IKK–NF-B
pathway in the liver of core-transgenic mice
TNF- and IL-1 are known to activate IB kinase
(IKK). IKK phosphorylates IB, leading to degradation by
proteasome. Loss of IB results in nuclear translocation
and activation of NF-B (Baeuerle, 1991). Therefore, we
determined the kinase activity of IKK derived from the
FIG. 3. The activity of AP-1 and expression of AP-1 responsible genes in the liver of core-transgenic (T) and nontransgenic (NT) mice. (A) AP-1
activation. Nuclear proteins were extracted from the liver of mice and incubated with 32P-labeled oligonucleotides containing the AP-1 binding
sequence and then loaded onto nondenaturing gels. Coomassie brilliant blue staining of nuclear extracts of the same samples is shown below. (B)
Competition assay. Shifted bands corresponding to the AP-1 signal in the 3-month-old, nontransgenic mouse, the same as described in (A), were
confirmed by the addition of excess amounts of unlabeled oligonucleotides. Lane 1, no unlabeled oligonucleotides; lane 2, the addition of 50-fold
unlabeled AP-1 binding consensus oligonucleotides; lane 3, the addition of 50-fold unlabeled NF-B binding consensus oligonucleotides. (C) The
expression of the AP-1 responsible gene in the liver of core-transgenic mice. Total RNA derived from the livers of mice was subjected to RT–PCR
(c-jun, 30 cycles; c-fos, 35 cycles; collagenase, 35 cycles; -actin, 20 cycles) using specific primers, and PCR products were separated on a 2%
agarose gel.
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liver of core-transgenic mice. IKK was immunoprecipi-
tated by anti-IKK-/ antibody, and an in vitro kinase
assay was performed using the GST–IB- (aa 1–54)
fusion protein as a substrate. As shown in Fig. 4A, the
IKK activity was almost equal in core-transgenic and
nontransgenic mice. We also determined the expression
of IB- in the liver of the mice. As mentioned above,
IB- was phosphorylated by IKK and rapidly degraded
by the ubiquitin–proteasome pathway, so IKK activity
should correlate negatively with IB- expression. As
shown in Fig. 4B, IB- expression in the liver of core-
transgenic mice was similar to that of nontransgenic
mice, further confirming that IKK activity was not acti-
vated by the core protein in core-transgenic mice.
We next examined by EMSA whether NF-B activation
reflected the IKK activity and IB- expression. As shown
in Fig. 4C, NF-B activation was not significantly more
enhanced in core-transgenic mice than in nontransgenic
mice, which was in contrast to the enhanced AP-1 activ-
ity in core-transgenic mice (Fig. 3A). The specificity of
these bands was confirmed by the addition of unlabeled
oligonucleotides (data not shown). These results sug-
gest that the IKK–NF-B pathway was not activated de-
spite the upregulation of TNF- and IL-1 in core-trans-
genic mice.
DISCUSSION
We previously demonstrated that HCV core-transgenic
mice develop steatosis and later HCC, indicating an
important role of the core protein in hepatocarcinogen-
esis (Moriya et al., 1997b, 1998). In core-transgenic mice,
the degree of the core protein expression, determined by
Western blotting and fluorescence enzyme immunoas-
say, was comparable with that in the liver of patients with
HCV-associated HCC (Koike et al., 2002). However, in
some works from other laboratories, transgenic mice
harboring HCV genes showed only mRNA expression
but not detectable levels of core protein. Reasons for this
may be technical issues in producing transgenic mice,
HCV and mouse strains, or the sensitivity of detection
systems, particularly antibodies, as discussed previously
(Koike et al., 2002). In our core-transgenic mice, (i) HCCs
were observed later in their lives, (ii) there was a gender
difference in HCC incidence, and (iii) histologically, no
inflammation was observed. These characteristics, ex-
cept for (iii), are analogous to HCV-related HCC in hu-
mans. Changes of some host factors may be involved in
HCC development as a consequence of the core protein
expression. We thus proceeded to investigate the differ-
FIG. 4. The activity of IKK and NF-B in the liver of core-transgenic (T) and nontransgenic (NT) mice. (A) The activity of IKK determined by in vitro
kinase assay. IKK was immunoprecipitated by anti-IKK antibody from lysates of mouse liver and incubated with GST–IB- in the presence of
[-32P]ATP. The lower panel shows densitometric analysis of the blots. Values were normalized by taking the density of the nontransgenic mice as
1 (relative kinase activity). Data shown are means SE (n  3 for each sample group). N. S., no statistically significant difference. (B) The expression
of IB- determined by Western blotting. Top, IB-; bottom, -actin. The intensity of the bands corresponding to IB- analyzed by densitometry and
the ratio of the intensity of IB- to that of -actin is shown below. (C) The NF-B activation determined by EMSA.
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ential expression of several genes related to cell prolif-
eration in the livers of core-transgenic mice.
In this study, we showed that the expression of TNF-
and IL-1 was significantly enhanced in core-transgenic
mice compared to that in nontransgenic littermates. The
enhancement of IL-6, in contrast, was not observed.
Furthermore, the JNK–AP-1 pathway was activated in the
liver cells, but the IKK–NF-B pathway, another down-
stream effector of these cytokines, was not enhanced.
These modifications of expression of cytokines and tran-
scription factors involved in the signal transduction path-
way were observed at as early as 2 months of age in
core-transgenic mice, as a consequence of the core
protein expression in the liver.
There are conflicting data concerning the association
of the core protein with NF-B activation in previous
studies using various cultured cells. Some reports dem-
onstrate that the core protein enhances NF-B activation
(Chung et al., 2001; Marusawa et al., 1999; You et al.,
1999), whereas other reports demonstrate that the core
protein suppresses TNF--induced NF-B activation
(Shrivastava et al., 1998) or does not modulate NF-B
activation in human-derived cells (Zhu et al., 1998). This
discrepancy may be due to the differences in the assay
systems or cell cultures used. The cells used in the
above studies were carcinoma cell lines or transformed
cell lines, and their expression levels of the core protein
seemed to be considerably higher than that in the liver of
HCV-infected patients. Recently, two studies demon-
strated that NF-B was activated in the liver tissue of
HCV-infected patients in contrast to that in normal
healthy adults (Boya et al., 2001; Tai et al., 2000). How-
ever, in these cases one cannot exclude the association
of cytokines released by leukocytes, which could con-
tribute to NF-B activation in the liver, since HCV-infected
liver tissue is generally accompanied by inflammatory
changes. Our core-transgenic mice expressed the core
protein in the liver at a level comparable to that of
HCV-infected patients (Koike et al., 2002; Moriya et al.,
1998) and exhibited no inflammatory changes throughout
their lives. Thus, our core-transgenic mouse model is
suitable for investigating the activation of transcription
factors, including NF-B, in the liver by the core protein,
and the core protein does not significantly enhance
NF-B activation in the liver, which was otherwise nor-
mal.
There are several reports demonstrating the associa-
tion of the core protein with TNF- signaling pathways
(Chen et al., 1997; Marusawa et al., 1999; Matsumoto et
al., 1997; Shrivastava et al., 1998; Zhu et al., 1998). The
core protein binds to the TNF receptor superfamily lym-
photoxin- receptor and the cytoplasmic domain of TNF
receptor 1 (TNFR1) (Matsumoto et al., 1997; You et al.,
1999; Zhu et al., 1998). Such binding implies that the core
protein may be involved in the apoptosis signaling path-
way and mechanisms of host immune defenses. The
present study, for the first time, demonstrates the in vivo
enhancement of TNF- expression in the liver by the
core protein, which was expressed in otherwise normal
liver. Hepatocytes as well as Kupffer cells produce
TNF- (Gonzalez-Amaro et al., 1994; Wordemann et al.,
1998); according to a previous study, significant TNF-
production was observed in hepatocytes with chronic
HCV infection, whereas TNF- was detected at low lev-
els in hepatocytes from normal individuals or patients
with alcoholic liver diseases (Gonzalez-Amaro et al.,
1994). In view of this report and our result here, the core
protein may up-regulate TNF- expression in hepato-
cytes of core-transgenic mice, as the core protein was
detected mainly in hepatocytes of the liver tissues
(Moriya et al., 1997b). Alternatively, the core protein ex-
pression in hepatocytes may indirectly up-regulate the
expression of the cytokines in nonparenchymal cells,
such as Kupffer or Kupffer-like cells. Further studies are
necessary to clarify this point.
We showed here that the expression of TNF- and
IL-1, but not IL-6, was enhanced in the liver of core-
transgenic mice. Although IL-6 expression is positively
regulated by several factors, such as TNF-, IL-1, AP-1,
and NF-B (Sehgal, 1992), the cooperative interaction of
mediators, including negative cross-talk, could be re-
quired to achieve the level of IL-6 expression. Indeed,
according to a previous report investigating the levels of
cytokines in sera in chronic liver diseases, the levels of
circulating IL-1 were closely correlated with that of
TNF-, whereas the IL-6 level correlated only weakly
with that of TNF- and did not correlate with that of IL-1
(Tilg et al., 1992). It is noteworthy that a vitronectin gene,
which was reported to be regulated positively by IL-6 and
negatively by TNF- and IL-1 (Seiffert et al., 1996), is
down-regulated in the liver of core-transgenic mice of all
ages (data not shown). Interestingly, a recent report
showed that gene expression of vitronectin was also
down-regulated in the liver of patients with chronic hep-
atitis C (Honda et al., 2001). This is compatible with the
enhanced expression of TNF- and IL-1 in the trans-
genic mice noted in our study. However, contrary to the
situation with HCV-infected human livers, our transgenic
mice expressed only the core protein. No HCV replica-
tion took place. Therefore, it may not be reasonable to
directly extrapolate the events that occur in the core-
transgenic mice with those in human livers. However,
several studies showed that the serum and intrahepatic
levels of TNF- and IL-1 were increased in HCV-in-
fected patients compared to those in healthy controls
(Larrea et al., 1996; Tilg et al., 1992). In view of such
reports and the fact that there is no in vitro culture
system for HCV, our core-transgenic mice are regarded
as one of the appropriate models for investigating HCV
pathogenesis. In addition, it should be noted that our
results were not obtained from cultured cells, which
already have properties of cancer cells, but from normal
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liver cells, which constitute the liver organ in living ani-
mals. Future work will be aimed at investigating the
mechanism of differential expression of these cytokines
in core-transgenic mice.
Our data suggest that the core protein enhances ac-
tivation of AP-1, a downstream effector of TNF- and
IL-1. Increased expression of these cytokines in core-
transgenic mice possibly contributes to AP-1 activation,
since JNK, which phosphorylates and activates c-Jun, a
component of AP-1, was also activated. In addition, en-
hanced expression of c-jun but not c-fos by AP-1 may
also contribute to AP-1 activation. Of course, several
other factors may also be associated with AP-1 activa-
tion. As reported previously, the core protein enhances
basal JNK activity by increasing the phosphorylated form
of MAPK kinase (Shrivastava et al., 1998). In addition, two
recent studies demonstrated contradictory effects of the
core protein on JNK activation; the core protein sup-
pressed TNF--induced JNK activation by disrupting the
TNFR1–TRADD–TRAF2 complex (Zhu et al., 2001), or en-
hanced basal and TNF--induced JNK activation by form-
ing a ternary complex with TNFR1 and TRADD (Park et
al., 2001). In view of these findings, it is possible that the
core protein also associates with this complex in core-
transgenic mice and influences the downstream path-
ways.
NF-B as well as AP-1 are downstream effectors of
these cytokines, but NF-B activation was not obviously
enhanced in the core-transgenic mice. Although the rea-
son for this inconsistency remains to be determined, one
possibility may be the alteration in the oxidant/antioxi-
dant status in core-transgenic mice (Shrivastava et al.,
1998). Previous studies have reported that overexpres-
sion of antioxidative enzymes like catalases and super-
oxide dismutase impairs NF-B activity (Manna et al.,
1998; Nilakantan et al., 1998). It has also been demon-
strated that antioxidants like pyrrolidine dithiocarbamate
and N-acetyl-L-cysteine activate AP-1 and suppress
NF-B (Meyer et al., 1993). Notably, biochemical analy-
ses revealed that our core-transgenic mice had en-
hanced antioxidative enzyme activity compared to non-
transgenic mice of the same age. For example, the cata-
lase activity in core-transgenic mice was 1.5 times higher
than that in nontransgenic mice. In addition, the total
amount of glutathione, the reduction of which plays a
central role in cellular defense against oxidative stress,
was significantly lower in core-transgenic mice (Moriya
et al., 2001). Taken together, the results lead us to con-
sider that AP-1 activity in core-transgenic mice could be
enhanced not only by increased expression of TNF-
and IL-1, but also by the enhancement of antioxidative
enzyme activity. Conversely, NF-B activity which is ac-
tivated by increased TNF- and IL-1 could be dimin-
ished by enhanced antioxidative enzyme activity.
In summary, HCV core protein promotes the expres-
sion of TNF- and IL-1 in the liver of core-transgenic
mice and activates the JNK–AP-1 pathway. These alter-
ations by the core protein may contribute to the devel-
opment of liver pathogenesis, including HCC in HCV
infection. Further studies are necessary to elucidate the
physiological relevance of differential expression of cy-
tokines and AP-1 activation to pathogenesis in persistent
HCV infection.
MATERIALS AND METHODS
Transgenic mice
Production of HCV core-transgenic mice (HCV geno-
type Ib, mouse strain C57BL/6) has been previously de-
scribed (Moriya et al., 1997b). Expression of the core
gene mRNA was detected by RT–PCR. Expression of the
core protein in the liver of core-transgenic mice was also
confirmed by immunohistochemical staining or Western
blotting (Moriya et al., 1997a,b; 1998). Several pairs of
male, core-transgenic and nontransgenic mice of 2 to 3
months old were used in this study. Core-transgenic
mice had very mild steatosis in the liver, but no inflam-
matory changes and tumorous lesions, whereas non-
transgenic mice had almost normal livers. The blood
cells were removed as much as possible from the livers
of mice when the mice were sacrificed.
RT–PCR
Mice were sacrificed and total RNA was extracted from
the liver using RNAzolB (TEL-TEST, Friendswood, TX). Three
micrograms of total RNA were reverse transcribed by Su-
perscript II (GIBCO BRL, Gaithersburg, MD) using oligo(dT)
primer. PCR of TNF-, IL-1, and GAPDH was performed
using the Quantitative PCR Detection Kit (BioSource Inter-
national, Camarillo, CA). This process can detect multiple
gene expression by amplifying all the genes under the
same conditions because the PCR primers in this kit have
similar melting temperatures and no obvious 3-end over-
lap to enhance multiple amplification. Primers for RT–PCR
of IL-6 and -actin were synthesized according to a previ-
ous report (Faulkner et al., 1995). Primers for the RT–PCR of
c-jun, c-fos, and collagenase were as follows: c-jun;
5-GCATGAGGAACCGCATTGCCGCCTCCAAGT-3 and 5-
TCAAAACGTTTGCAACTGCTGCGTTAGCAT-3; c-fos: 5-
TCCTTGAGCATGCCCGTGTCTTAT-3 and 5-AGACAA-
AGGAAGACGTGTAAGTAGTGCAGCC-3; collagenase:
5-ATTCCCAAAAGAGGTGAAGAGACT-3 and 5-TATG-
GAATTTGTTGGCATGACTCT-3. For the RT–PCR, the quan-
tity of cDNA template and the number of amplification
cycles were optimized to ensure that the reaction was
terminated during the linear phase of product amplification
so that semiquantitative comparisons of the mRNA abun-
dance between different samples were possible.
Southern blotting
Five microliters of PCR products was separated on a
1.5% agarose gel containing 1 TBE buffer, denatured
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twice in denaturing buffer (0.5 N NaOH, 1.5 M NaCl) for
15 min, neutralized twice in neutralization buffer [0.5 M
Tris–HCl (pH 7.5), 3 M NaCl], and transferred onto a
Hybond-N membrane filter (Amersham, Buckingham-
shire, UK) in 20 SSC [3 M NaCl, 0.3 M trisodium citrate
dihydrate (pH 7.0)]. The filter was dried, and DNAs were
fixed on the membrane by irradiation with UV light and
then hybridized with an appropriate heat-denatured
probe in hybridization buffer [50% deionized formamide,
5 SSC, 2% blocking reagent (Boehringer Mannheim,
Mannheim, Germany), 0.02% SDS, 0.1% N-lauroyl salco-
sin, 0.1 mg/ml of salmon sperm DNA] overnight after
prehybridization in the same buffer without a probe for
3 h. Probes were prepared by amplifying and digoxigenin
(DIG) labeling the positive control DNA provided in the kit
used for PCR. After hybridization, the filter was washed
twice with 2 wash buffer (2 SSC, 0.1% SDS) for 5 min
and then twice with 0.1 wash buffer (0.1 SSC, 0.1%
SDS) for 15 min. DIG-labeled DNA probes were detected
using the DIG Luminescent Detection Kit (Boehringer
Mannheim).
Real-time PCR
TaqMan probes were labeled with a reporter fluores-
cent dye [6-carboxy-fluorescein (FAM)] at the 5-end and
a quencher fluorescent dye [6-carboxy-tetramethyl-rho-
damine (TAMRA)] at the 3-end. Primers and the TaqMan
probes for TNF- and IL-1 were as follows: TNF-
forward primer, 5-CAGACCCTCACACTCAGATCATCT-3;
reverse primer, 5-CCACTTGGTGGTTTGCTACGA-3;
probe, 5-(FAM)TCGAGTGACAAGCCTGTAGCCCACGT-
(TAMRA)-3. IL-1 forward primer, 5-TGGGCCTCAAAG-
GAAAGAATC-3; reverse primer, 5-GACAAACCGCTTT-
TCCATCTTC-3; probe, 5-(FAM)TGCAGCTGGAGAGTGT-
GGATCCCAA(TAMRA)-3. Fifty microliters of reaction
mixture was used, and it contained 100 ng of extracted
total RNA, 0.3 mmol/L forward and 0.9 mmol/L reverse
primers, 0.2 mmol/L TaqMan probe, and the TaqMan
One-Step RT–PCR Master Mix Reagents Kit (Applied
Biosystems, Foster City, CA). The conditions of one-step
RT–PCR were as follows: 30 min at 48°C, 10 min at 95°C,
and then 60 cycles of amplification for 15 s at 95°C and
1 min at 60°C. The assay used an instrument capable of
measuring fluorescence in real time (ABI Prism 7700
Sequence Detector; Applied Biosystems). The calibration
curve, covering the range from 1.6 ng to 1 g total
RNA/50 l reaction, was created using Mouse Liver Total
RNA (Ambion, Austin, TX). The same procedure was
performed using TaqMan Rodent GAPDH Control Re-
agents (Applied Biosystems) as an internal control.
ELISA
ELISAs for TNF- and IL-1 were performed using
Mouse TNF- and IL-1 ELISA Kits (BioSource). Samples
were prepared according to a previous paper (Casta-
gliuolo et al., 1998). The ELISA was performed by tripli-
cate for each sample. The amount of total proteins in
each sample was determined with the BCA Protein As-
say Kit (Pierce, Rockford, IL), and the concentrations of
the cytokines in the livers were calculated.
In vitro kinase assay
The activities of JNK and ERK were determined using
the SAPK/JNK and the p44/42 MAPK Assay Kit (Cell
Signaling Technology, Beverly, MA), respectively. Liver
tissues of the mice were homogenized in the lysis buffer
provided in the kit, and subsequent assays were per-
formed according to the manufacturer’s protocols. The
IKK assay was performed using a similar procedure
shown in a previous report (Chung et al., 2001). Liver
tissues were homogenized in 50 mM Tris–HCl (pH 8.0),
100 mM NaCl, 1 mM sodium orthovanadate, 1 mM NaF,
0.5 mM -glycerolphosphate, and Protease Inhibitor
Cocktail (Complete; Roche Molecular Biochemicals, In-
dianapolis, IN). Homogenates were sonicated four times
for 5 s and then centrifuged at 14,000 rpm for 10 min.
Supernatant containing 500 g of proteins was incu-
bated overnight with anti-IKK-/ antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) bound to Protein Sepha-
rose 4B beads (Amersham). Immunoprecipitates were
washed three times and the kinase reaction was per-
formed in the same buffer with 10 Ci [-32P]ATP, 2 mM
MgCl2, 1 mM DTT, and 1 g of GST–IB- (aa 1–54)
fusion protein as a substrate. GST–IB- was prepared
in Escherichia coli and purified using GST Sepharose
Beads (Amersham). The reaction mixture was then sep-
arated by SDS–PAGE followed by autoradiography.
Electrophoretic mobility shift assay
Nuclear extracts from the livers of core-transgenic and
nontransgenic mice were prepared according to the pro-
cedure in a previous report (Deryckere and Gannon, 1994).
The double-stranded oligonucleotides (AP-1, 5-CGCTT-
GATGAGTCAGCCGGAA-3; NF-B, 5-AGTTGAGGGGAC-
TTTCCCAGGC-3) were end-labeled with [-32P]ATP. La-
beled oligonucleotides were incubated on ice for 30 min,
along with 5 g of nuclear extracts, in 30 l of binding
buffer [10 mM Tris–HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA,
10% glycerol, 1 mM DTT, 1 mM PMSF, and 2 g of poly(dI–
dC)]. The binding reactions detecting the AP-1 activity con-
tained 5 mM MgCl2 (Meyer et al., 1993). The reaction mix-
ture was analyzed by electrophoresis on a 7% nondenatur-
ing polyacrylamide gel containing 4% glycerol in 0.25
TBE. For competition experiments, a 50-fold excess of un-
labeled, identical oligonucleotides or unrelated oligonucle-
otides (the NF-B sequence for AP-1 assay, and the AP-1
sequence for NF-B assay, respectively) was added 20 min
before the addition of labeled oligonucleotides. AP-1 activity
was determined by measuring the intensity of the shifted
band by densitometer (NIH Image; National Institutes of
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Health, Bethesda, MD). A serial 2-fold dilution of purified
c-Jun protein (rhAP1; Promega, Madison, WI) was used as
a control, and the intensity of each band was measured for
standard curves.
Western blotting
Tissue lysates were mixed with SDS sample buffer
and sonicated for 5 min. Boiled samples were separated
by 10% SDS–PAGE and electrotransfered to a PVDF
membrane. After blocking, the membrane was probed
with anti-IB- antibody (Cell Signaling Technology) or
anti--actin antibody (Sigma Chemical Co., St. Louis,
MO), followed by anti-rabbit IgG conjugated with horse-
radish peroxidase, and visualized by the Phototope-HRP
Western Detection System (Cell Signaling Technology).
Statistical analysis
Results are expressed as means  SE. The signifi-
cance of the differences of means was determined using
Mann–Whitney’s U test.
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